drugset
drugset / Trial / NCT00219271

Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

NCT00219271 ↗

Phase 4 Completed 60 enrolled Novartis Pharmaceuticals University of Athens · collab
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer

Timeline

Start
2003-09
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 4 mg Intravenous

Indications

prostate cancer